drugset / Trial / NCT01347086

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

NCT01347086

Phase 1 Completed 60 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of the study is to evaluate safety, tolerability and pharmacokinetics in Asian and Caucasian healthy male volunteers administered BI 207127 NA.

Timeline

Start
2011-05
Primary completion
2011-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Deleobuvir Small molecule 400 mg Oral
Subject Deleobuvir Small molecule 800 mg Oral
Subject Deleobuvir Small molecule 1200 mg Oral

Indications

No indication recorded.